22. もやもや病 Moyamoya disease Clinical trials / Disease details
臨床試験数 : 17 / 薬物数 : 22 - (DrugBank : 17) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 45
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs071220048 | 29/08/2022 | 29/08/2022 | Angiogenesis augmentation therapy for indirect revascularization of moyamoya disease using G-CSF | Angiogenesis augmentation therapy for indirect revascularization of moyamoya disease using G-CSF - EDFAPS-G | Moyamoya disease Moyamoya disease, indirect revascularization, Granulocyte-Colony Stimulating Factor;D009072 | G-CSF(75 micrograms/body) is applied intraoperatively to the indirect revascularization site, and G-CSF (75 micrograms/body) is given intravenously once daily for 2 days. | Morioka Motohiro | NULL | Recruiting | >= 20age old | <= 60age old | Both | 5 | Phase 1-2 | Japan |